Future Science Group
Browse
MO8833A_supplementary_materials_v2_Figures.pdf (646.42 kB)
Download file

Supplementary Figures – Indirect comparison of pembrolizumab monotherapy versus nivolumab+ipilimumab in first-line metastatic lung cancer

Download (646.42 kB)
figure
posted on 2022-01-25, 09:05 authored by Figshare Future Science GroupFigshare Future Science Group, Balazs Halmos, Thomas Burke, Chrysostomos Kalyvas, Ralph Insinga, Kristel Vandormael, Andrew Frederickson, Bilal Piperdi

Figure S1

Kaplan–Meier curves before matching adjustment for a) overall survival b) progression-free survival

Figure S2

Forest plot of pembrolizumab versus nivolumab+ipilimumab for overall survival and progression-free survival in patients with PD-L1 TPS 1–49% and ≥50%a

Funding

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

History

Usage metrics

    ImmunotherapyImmunotherapy

    Categories

    Keywords

    non-small-cell lung cancerpembrolizumabnivolumabcomparative effectivenessCancer Therapy (excl. Chemotherapy and Radiation Therapy)Solid Tumours

    Licence

    CC BY-NC-ND 4.0

    Exports